Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours.

14 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

31 Dec 2014

Vermillion closes previously announced private placement with investors

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses.

25 Dec 2014

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Oncolytics Biotech Inc. ("Oncolytics") today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

22 Dec 2014

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Myriad Genetics, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca’s drug Lynparza™ (olaparib).

22 Dec 2014

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

A common polymorphism - a variation in a person's DNA sequence that is found with regularity in the general population - can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research from The Wistar Institute that was published online by the journal Cancer Cell.

19 Dec 2014

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.

18 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

Scientists have long known the p53 protein suppresses tumors. However, a recent animal study by UC Davis researchers has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels. Too much Rbm38 reduces p53 levels, increasing the risk of cancer.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

MD Anderson study sheds light on miR569 gene

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

9 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

2 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Cedars-Sinai Medical Center releases November tip sheet of story ideas

Following is the November 2014 tip sheet of story ideas from Cedars-Sinai Medical Center.

27 Nov 2014

Pathology specialist publishes invited commentary on breast cancer gene screening

There has been much recent debate on the benefits and risks of screening for breast cancer using BRCA1 and BRCA2 mutations in the general adult population.

27 Nov 2014

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

Removing ovaries at hysterectomy does not increase a woman's risk of pelvic organ prolapse after menopause. In fact, removing ovaries lowers the risk of prolapse. This surprising finding from a Women's Health Initiative study was published online this week in Menopause, the journal of The North American Menopause Society.

27 Nov 2014

New Sophia DDM platform offers full BRCA1/2 analysis on a single NGS run

Sophia Genetics, the European leader in Clinical Genomics and Next Generation DNA Sequencing (NGS), has today launched a major upgrade to its Data Driven Medicine Platform (Sophia DDM), offering full BRCA1/2 analysis on a single NGS (Next Generation Sequencing) run, for the first time.

26 Nov 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

26 Nov 2014

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Vermillion closes previously announced private placement with investors

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

MD Anderson study sheds light on miR569 gene

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

Faster and more accurate method for testing new cancer drugs

Cedars-Sinai Medical Center releases November tip sheet of story ideas

Pathology specialist publishes invited commentary on breast cancer gene screening

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

New Sophia DDM platform offers full BRCA1/2 analysis on a single NGS run

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in